To investigate the impact of SF3B1 mutation on splicing in CLL, we first used RNA-seq data from tumor B cells from 298 patients diagnosed with CLL from the International Cancer Genome Consortium (ICGC) (Puente et al, 2015) and B cell samples from four healthy donors. Here, SF3B1 is linked to neoplasm.